Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

    By Global Biodefense StaffMarch 2, 2021
    A nurse tests students for COVID-19 as they arrive on the UC San Diego campus. Credit: Erik Jepsen / UC San Diego
    Share
    Facebook LinkedIn Reddit Email

    University of California San Diego was awarded five Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health (NIH), totaling nearly $33 million over four years. The purpose of the RADx initiative is to speed innovation in the development, commercialization and implementation of technologies for COVID-19 testing.

    There are several programs within the RADx initiative, including the RADx Underserved Populations (RADx-UP) program, which funds projects aimed at understanding why some communities are disproportionately affected by COVID-19 and reducing the factors associated with these disparities, and the RADx Radical (RADx-rad) program, which supports innovative approaches to addressing gaps in COVID-19 testing.

    “The RADx program responds to the nation’s need for innovative solutions in diagnostic technologies that are people-centric, and utilize expertise in infectious diseases, informatics, data science, clinical pathology, bioengineering and many other related areas,” said Lucila Ohno-Machado, MD, PhD, chair of the Department of Biomedical Informatics at UC San Diego Health. “It includes, for example, artificial intelligence models that will help detect and prognosticate disease using novel sensors. Lessons learned from the current focus on COVID-19 will be leveraged in many other health sciences challenges, and data will be shared to accelerate other discoveries.”

    UC San Diego’s RADx-rad and RADx-UP projects include:

    RADx-rad Discoveries & Data: Consortium Coordination Center Program Organization
    Project Leaders: Lucila Ohno-Machado, MD, PhD, chair of the Department of Biomedical Informatics at UC San Diego Health, professor of medicine and associate dean for informatics and technology at UC San Diego School of Medicine, and founding faculty member of UC San Diego Halicio?lu Data Science Institute; Eliah Aronoff-Spencer, MD, PhD, assistant professor of medicine at UC San Diego School of Medicine and Qualcomm Institute at UC San Diego; Hua Xu, PhD, of University of Texas Health.
    Amount: $23,817,692 over four years
    This project will use advanced data management to coordinate a consortium of innovative COVID-¬19 diagnostic technology developers. The partnership between UC San Diego and the University of Texas Health Science Center at Houston brings together informatics/data scientists and infectious diseases specialists who will standardize viral samples, testing and procedures and data, in order to integrate and share data in a meaningful manner.

    Harnessing Technological Innovation and Community-Engaged Implementation Science to Optimize COVID-19 Testing for Women and Children in Underserved Communities
    Project Leaders: Robert Tukey, PhD, professor of pharmacology at UC San Diego School of Medicine; Louise Laurent, MD, PhD, professor of obstetrics, gynecology and reproductive sciences, vice chair for translational research and director of perinatal research at UC San Diego School of Medicine
    Amount: $4,970,492 over two years
    This study seeks to maximize COVID-19 testing among pregnant women and children in an area of San Diego near the United States-Mexico border that has been noted to have the highest local incidence of COVID-19.

    COVID-19 testing in Underserved and Vulnerable Populations Receiving Care in San Diego Community Health Centers
    Project Leaders: Jesse Nodora, DrPH, associate professor in the Herbert Wertheim School of Public Health and Human Longevity Science and director of Community Engagement at the Altman Clinical and Translational Research Institute at UC San Diego; Linda Hill, MD, professor, Herbert Wertheim School of Public Health; María Elena Martínez, PhD, professor in the Herbert Wertheim School of Public Health, Sam M. Walton Endowed Chair for Cancer Research, and associate director of Population Science, Disparities and Community Engagement at UC San Diego Moores Cancer Center
    Amount: $1,692,794 over two years
    In partnership with Health Quality Partners of Southern California and the laboratory of Louise Laurent, MD, PhD, at UC San Diego School of Medicine, the study will develop, test and evaluate a rapid, scalable capacity building project to enhance COVID-19 testing in three regional community health centers in San Diego County. Testing will be conducted among asymptomatic individuals who are at increased risk for severe COVID illness. Investigators will also gather insights from patients, providers, health center leadership and community stakeholders to establish best practices for future scale-up of COVID-19 testing sustainability and vaccination.

    Diagnosing and Predicting Risk in Children with SARS-CoV-2- Related Illness
    Project Leader: Jane Burns, MD, pediatrician at Rady Children’s Hospital-San Diego and director of the Kawasaki Disease Research Center at UC San Diego School of Medicine
    Amount: $1,396,830 over two years
    This project will define the antibody repertoire against all known human coronaviruses and determine how pre-existing antibodies to other coronaviruses may shape the immune response in acuteSARS-CoV-2 infection and multisystem inflammatory syndrome in children.

    Validation of Smart Masks for Surveillance of COVID-19
    Project Leader: Jesse Jokerst, PhD, professor of nanoengineering at UC San Diego Jacobs School of Engineering
    Amount: $1,045,704 over three years
    This project will develop a “smart mask” that changes colors when exposed to enzymes of COVID-19 (Mpro and PLP proteases specific to the SARS viruses) found in saliva. The mask concentrates them from aerosolized saliva when the subject breathes and speaks. Biobank saliva samples are being leveraged to help determine the specificity of the mask.

    Awards Bioinformatics COVID-19 Editor Pick Medicine-Health Rapid Diagnostics Virology
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleNew Coronavirus Variant: Here Is What Scientists Know About B1525
    Next Article Ebola: CDC to Require Airlines to Collect Passenger Information if Traveling from DRC and Guinea

    Related Stories

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.